JP2025511403A5 - - Google Patents

Info

Publication number
JP2025511403A5
JP2025511403A5 JP2024559036A JP2024559036A JP2025511403A5 JP 2025511403 A5 JP2025511403 A5 JP 2025511403A5 JP 2024559036 A JP2024559036 A JP 2024559036A JP 2024559036 A JP2024559036 A JP 2024559036A JP 2025511403 A5 JP2025511403 A5 JP 2025511403A5
Authority
JP
Japan
Prior art keywords
prostate cancer
azd5305
metastatic
pharmaceutical product
abiraterone acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559036A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511403A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/059123 external-priority patent/WO2023194525A1/en
Publication of JP2025511403A publication Critical patent/JP2025511403A/ja
Publication of JP2025511403A5 publication Critical patent/JP2025511403A5/ja
Pending legal-status Critical Current

Links

JP2024559036A 2022-04-07 2023-04-06 癌を治療するための併用療法 Pending JP2025511403A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263362614P 2022-04-07 2022-04-07
US63/362,614 2022-04-07
PCT/EP2023/059123 WO2023194525A1 (en) 2022-04-07 2023-04-06 Combination therapy for treating cancer

Publications (2)

Publication Number Publication Date
JP2025511403A JP2025511403A (ja) 2025-04-15
JP2025511403A5 true JP2025511403A5 (https=) 2026-04-10

Family

ID=86184958

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559036A Pending JP2025511403A (ja) 2022-04-07 2023-04-06 癌を治療するための併用療法

Country Status (11)

Country Link
US (1) US20250228847A1 (https=)
EP (1) EP4504147A1 (https=)
JP (1) JP2025511403A (https=)
KR (1) KR20240170958A (https=)
CN (1) CN118973555A (https=)
AU (1) AU2023250030A1 (https=)
CA (1) CA3254950A1 (https=)
IL (1) IL316019A (https=)
MX (1) MX2024012369A (https=)
TW (1) TW202404592A (https=)
WO (1) WO2023194525A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE201445T1 (de) 1994-08-12 2001-06-15 Myriad Genetics Inc Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens
ATE198623T1 (de) 1994-08-12 2001-01-15 Myriad Genetics Inc Verfahren zum nachweis von prädisposition von ovarial- und brustkrebs
HUE060460T2 (hu) * 2017-04-13 2023-03-28 Janssen Pharmaceutica Nv Niraparib, abirateron-acetát és prednizon prosztatarák kezelésére
SI3999506T1 (sl) 2019-07-19 2025-06-30 Astrazeneca Ab Zaviralci PARP1
TW202228693A (zh) * 2020-10-08 2022-08-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法

Similar Documents

Publication Publication Date Title
JP2024015120A5 (https=)
JP2022180461A5 (https=)
JP2023041862A5 (https=)
JP5890780B2 (ja) 中枢を介する悪心および嘔吐を治療するための組成物および方法
CA2856646C (en) Combination treatment of cancer
JP2020516646A5 (https=)
TW201210593A (en) Compositions and methods for treating centrally mediated nausea and vomiting
CN107872975A (zh) 用于治疗恶心和呕吐的氨磺必利和其它止吐药的组合
IL320452A (en) Combination therapy for prostate cancer
JP2021509395A5 (https=)
WO2005070043A2 (en) Methods for treating non-melanoma cancers with paba
TWI441639B (zh) 用於治療卵巢癌之包含紫杉醇之組合
TW202539655A (zh) Glp-1受體非肽促效劑化合物之口服投藥
JP2024523559A5 (https=)
JP2023522415A5 (https=)
JP2016505050A5 (https=)
JP2004525143A5 (https=)
JP2025511402A5 (https=)
JP2025511401A5 (https=)
JP2022543679A5 (https=)
JP2024540044A5 (https=)
JP2010504307A5 (https=)
EP4494700A3 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
JP2022177119A5 (https=)
JP2025511403A5 (https=)